Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
4.350
+0.320 (7.94%)
Dec 20, 2024, 4:00 PM EST - Market closed
Fulcrum Therapeutics Revenue
Fulcrum Therapeutics had revenue of $80.87M in the twelve months ending September 30, 2024, up 2,987.86% year-over-year. In the year 2023, Fulcrum Therapeutics had annual revenue of $2.81M, down -55.77%.
Revenue (ttm)
$80.87M
Revenue Growth
+2,987.86%
P/S Ratio
3.34
Revenue / Employee
$1,064,092
Employees
76
Market Cap
234.63M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aurora Cannabis | 219.84M |
biote | 193.06M |
LifeMD | 193.06M |
BGM Group | 29.87M |
Profound Medical | 8.98M |
Ocugen | 4.70M |
Precigen | 3.96M |
Cardiff Oncology | 688.00K |
FULC News
- 25 days ago - Fulcrum Therapeutics to Participate in Upcoming December Conferences - GlobeNewsWire
- 5 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares - GuruFocus
- 2 months ago - Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud - Accesswire
- 2 months ago - Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation - Accesswire